With the success of trials and the FDA approval of a number of ICI drugs in different solid tumors, including EC [16], driven by the knowledge that PD-L1 staining is one of the reliable predictive biomarkers [10,29], the contribution of CAF-mediated signals in influencing the tumor immune environment is undeniable [30]. This evidence concerns the gene CD274 and neoplasm.